<p><strong>Pediatric Use</strong>: The safety and effectiveness of Ticagrelor in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: No overall differences in safety or effectiveness were observed in geriatric patients.<br />
<br />
<strong>Hepatic Impairment</strong>: Ticagrelor has not been studied in the patients with moderate or severe hepatic impairment. Ticagrelor is metabolized by the liver and impaired hepatic function can increase risks for bleeding and other adverse events. Hence,<br />
<br />
<strong>Renal Impairment</strong>: No dosage adjustment is needed in patients with renal impairment. Patients receiving dialysis have not been studied.</p>